Promoted Content Promoted Content

X

Find Novel Oncology Drugs in Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KM257

            Therapeutic Area: Oncology Product Name: KM257

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Xuanzhu Biopharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 27, 2021

            Details:

            Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.